Journal September 17, 2026 6 min read

MOTS-c vs 5-Amino-1MQ: what the research actually compares

A side-by-side look at what published studies have measured for MOTS-c and 5-Amino-1MQ, where the evidence is stronger, and what remains unknown.

peptides-pro Editorial

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a mitochondrial-encoded peptide, also described as a mitochondrial-derived peptide (MDP) or mitokine, with the sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg [4]. 5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT); the evidence block does not provide its formula, molecular weight, or other identifiers. The work on MOTS-c centres on mitochondrial metabolic signalling, oxidative stress, and inflammatory pathways, including NLRP3 inflammasome and Nrf2 activation [2][4].

For 5-Amino-1MQ, the evidence block contains no published studies; therefore, no research findings can be reported for it here. The comparison below is limited to what the literature supports for MOTS-c and notes the absence of comparable data for 5-Amino-1MQ.

Research Studies

MOTS-c and host defence peptide activity

MOTS-c was identified as a mitochondrial-encoded amphipathic and cationic peptide with direct antibacterial and immunomodulatory functions, consistent with known host defence peptides [1]. The study reported that MOTS-c targeted Escherichia coli and other pathogens, and that it is encoded in the human mitochondrial genome, presumably deriving from primordial proto-mitochondrial bacteria [1]. This work was conducted in laboratory models and does not establish clinical effects.

MOTS-c and inflammasome activation in a diabetic rat model

In a high-fat diet and streptozotocin-induced type 2 diabetes rat model, MOTS-c treatment significantly reduced fasting blood glucose and circulating C-reactive protein levels, while selectively modulating plasma inflammatory markers [2]. The study investigated NLRP3 inflammasome activity in systemic and cardiac tissues, reporting suppression of inflammasome activation [2]. These findings are specific to the animal model used.

MOTS-c and circulating levels in Hashimoto's thyroiditis

A cross-sectional study compared 90 patients with Hashimoto's thyroiditis to age- and sex-matched healthy controls and found reduced circulating MOTS-c levels in the patient group [3]. The authors interpreted this as reflecting integrated autoimmune and metabolic dysregulation [3]. As a cross-sectional design, it cannot establish causality or directionality.

MOTS-c and engineered R13A-MOTS-c in radiation-induced lung injury

To address poor membrane permeability of wild-type MOTS-c, researchers engineered R13A-MOTS-c by substituting the polar arginine at position 13 with alanine, increasing the hydrophobicity index from -0.938 to -0.544 [4]. Functional uptake assays, including competition with canonical LAT1 substrates (leucine, BCH) and LAT1 knockdown, confirmed that R13A-MOTS-c enters cells via LAT1-mediated delivery [4]. In a model of radiation-induced lung injury, R13A-MOTS-c attenuated injury via Nrf2 activation and mitochondrial protection [4]. These results pertain to the engineered variant, not wild-type MOTS-c.

MOTS-c and atrial fibrillation in human tissue and mouse models

Human atrial tissues were analysed using public GEO data, immunohistochemistry, and immunofluorescence, alongside an AngII-induced mouse model and primary cardiac cells [5]. The study reported that humanin and MOTS-c expression was altered in atrial fibrillation and that both peptides attenuated atrial fibrillation by suppressing fibrosis and mitochondrial dysfunction [5]. The evidence block does not provide plasma level data or effect sizes.

MOTS-c and myocardial ischemia-reperfusion injury in acute myocardial infarction

In a cross-sectional study of 72 acute myocardial infarction patients undergoing percutaneous coronary intervention, serum MOTS-c levels were measured in peripheral and intracoronary blood [6]. Patients were divided into MIRI (n=34) and non-MIRI (n=38) groups, and the association between MOTS-c levels and myocardial ischemia-reperfusion injury was investigated [6]. The evidence block does not state the direction or magnitude of the association.

MOTS-c and polycystic ovary syndrome in adolescents

A study investigated differences in MOTS-c levels between adolescents diagnosed with polycystic ovary syndrome and those without, as well as associations with metabolic parameters and the m.1382A>C polymorphism [7]. The evidence block does not report the results of these comparisons.

MOTS-c and renal transplantation under different anaesthetic techniques

A prospective controlled trial (NCT07678073) aims to compare the effects of sevoflurane general anaesthesia and combined spinal-epidural anaesthesia on ferroptosis, humanin, and MOTS-c levels in kidney transplant recipients [8]. The study is designed to assess whether anaesthetic technique affects these biomarkers in the context of ischemia-reperfusion injury [8]. No results are available in the evidence block.

MOTS-c in sepsis-induced cardiomyopathy and other reference-only findings

Additional papers report that MOTS-c has been studied in sepsis-induced cardiomyopathy, where it is characterised as a mitochondrial-derived peptide involved in inflammatory dysregulation, mitochondrial dysfunction, and metabolic disturbance [9]. In human mesenchymal stromal cells, MOTS-c activated metabolic signalling but blunted reparative function [10]. A further review discusses MOTS-c as a secreted mitochondrial microprotein with intracrine, paracrine, and endocrine effects, and its potential in inflammatory lung diseases [11]. Another study reports that MOTS-c preserves mitochondrial subpopulation bioenergetics and genome integrity to attenuate cardiac ischemia-reperfusion injury [12]. These are reference-only items and are not the focus of this page.

5-Amino-1MQ and NNMT inhibition

The evidence block contains no published studies on 5-Amino-1MQ. Therefore, no research findings, mechanisms, or model data can be reported for this compound in this article.

Comparison table

Feature	MOTS-c	5-Amino-1MQ
Class	Mitochondrial-derived peptide (mitokine) [1]	Small-molecule NNMT inhibitor (no evidence in block)
Identifiers	Sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg [4]	Not provided in evidence block
Reported mechanisms	Antibacterial, immunomodulatory, NLRP3 suppression, Nrf2 activation, LAT1-mediated uptake (engineered variant) [1][2][4]	Not reported in evidence block
Models studied	Diabetic rat, mouse atrial fibrillation, human cross-sectional (HT, AMI, PCOS), cell models [2][3][5][6][7]	None in evidence block
Human data	Cross-sectional associations in HT, AMI, PCOS; trial in renal transplantation [3][6][7][8]	None in evidence block
Evidence strength	Multiple preclinical and observational studies; no clinical outcome trials reported in block	No published studies available in block

What the literature supports

The published work on MOTS-c includes in vitro, animal, and human observational studies, with findings spanning host defence, inflammasome modulation, oxidative stress, and mitochondrial function [1][2][4][5]. Human data are largely cross-sectional and associative, and the evidence block does not contain randomised controlled trials of MOTS-c as an intervention [3][6][7]. For 5-Amino-1MQ, the evidence block provides no studies, so no comparison of mechanisms, models, or outcomes can be made. The literature does not support declaring a winner; it supports the statement that MOTS-c has a documented research base in the areas listed, while 5-Amino-1MQ does not, within the evidence available here.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.